Biotech

All Articles

Biogen, UCB document phase 3 lupus gain after stopping working earlier trial

.Biogen and also UCB's gamble on improving into period 3 on the back of an unsuccessful study tries ...

Aptadir hopes new RNA inhibitors may turn around difficult cancers

.Italian biotech Aptadir Rehabs has actually introduced along with the assurance that its pipe of pr...

Wave surfs DMD excellence to regulators' doors, sending out stock up

.Surge Life Sciences has actually met its own goal in a Duchenne muscular dystrophy (DMD) research, ...

Sanofi picks brand new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, occupying the...

Achilles drops tissue treatment plan, bandages for discharges after overlooking 'commercial viability' goals

.Achilles Rehabs has torn up its own method. The British biotech is actually knocking off on its cli...

Aligos advertises phase 2 MASH gain, slashing liver excess fat up to 46%

.Aligos Therapies is actually declaring a midstage gain in metabolic-dysfunction affiliated steatohe...

Basilea scores $268M BARDA backing for antifungals, antibiotics

.Basilea Pharmaceutica's job developing new antifungals has actually obtained a notable increase fro...

Capricor sells Europe civil liberties to late-stage DMD therapy for $35M

.Having actually scooped up the USA liberties to Capricor Therapies' late-stage Duchenne muscular dy...

FDA fragments adcomm for Applied's unusual illness drug

.After pushing back the selection meeting for Applied Rehabs' metabolic problem drug govorestat, the...

Novo inks $600M NanoVation package to examine hereditary drugs ex-liver

.Novo Nordisk is actually proceeding its own push in to hereditary medications, agreeing to pay Nano...